COMMUNIQUÉS West-GlobeNewswire

MediciNova CEO Provides Shareholder Update
12/10/2026
LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
BSACI 2026: New preference and ease-of-use data comparing EURneffy® nasal adrenaline spray and adrenaline auto-injector trainer devices
12/10/2026
New UK comparative study data assessing patient preferences between trainer devices suggest EUR neffy ® is viewed as less burdensome than adrenaline auto-injectors (AAIs) 1 After trying both trainer devices, patients [...]
Novo Nordisk A/S - share repurchase programme
12/10/2026
Bagsværd, Denmark, 12 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
12/10/2026
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance 1 at 6 months, and these changes were maintained at 24 months (a [...]
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
12/10/2026
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on [...]
Vivani Medical Announces Participation in Upcoming Investor Conferences
12/10/2026
ALAMEDA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants [...]
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
12/10/2026
– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically [...]
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
12/10/2026
The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027. Current [...]
Beacon Therapeutics Presents Data from Pivotal VISTA Trial of Laru-zova at AAO 2026
12/10/2026
Late-breaking oral presentation at Retina Subspecialty Day outlines data from Beacon’s pivotal VISTA trial, which met its FDA-endorsed primary endpoint with statistical significance 31.0% of participants in the high [...]
Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
12/10/2026
Study reports sustained IOP reduction and reduced medication burden over 24 months SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based [...]
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
12/10/2026
Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus [...]
How Specialty Retailers Keep Brand Voice When Outsourcing Customer Service
12/10/2026
After Transcom trained dedicated teams inside Dacor's own learning center, the luxury appliance brand saw resolution times fall 45% and first-time fix rates improve 60%, with an 82% CSAT score Outsourced voice can break [...]
Kraig Biocraft Laboratories Files for Expanded Investment License to Fuel Spider Silk Production Growth
12/10/2026
ANN ARBOR, Mich., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that it has [...]
NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury
12/10/2026
RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injury Study builds on functional improvements observed in [...]
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
12/10/2026
On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the median 24-week biomarker data [...]
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
12/10/2026
Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low [...]
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
12/10/2026
Vancouver, Canada, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
12/10/2026
Topline induction results expected in the second half of 2027 BOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company [...]
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
12/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]

Pages